The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

Biocon Biologics scored an FDA approval for its Stelara biosimilar, marketed as Yesintek, the company announced Monday.

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

Biocon Biologics Ltd announced today that the U.S. Food and Drug Administration has approved YESINTEK™ (Ustekinumab-kfce), a ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Biocon Biologics the biosimilars company and subsidiary of Indian drugmaker Biocon, has announced that the US Food and Drug ...

US FDA approves Biocon Biologics’ Yesintek, Bmab 1200 biosimilar to J&J's Stelara: Our Bureau, Bengaluru Monday, December 2, 2024, 16:15 Hrs [IST] Biocon Biologics subsidiary of ...

Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the green. Nifty 50 closed at 24,131.10, ...

Yesintek, a monoclonal antibody, is approved for the treatment of Crohn's disease, olcerative colitis, plaque psoriasis, and ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...